Core Viewpoint - The collaboration between Insilico Medicine and Qilu Pharmaceutical Group focuses on drug development in the cardiovascular and metabolic disease sectors, leveraging Insilico's Pharma.AI platform for small molecule inhibitor development [1] Group 1: Partnership Details - Insilico Medicine has signed a strategic cooperation agreement with Qilu Pharmaceutical Group and its subsidiary, Shanghai Qilu Pharmaceutical Research Center [1] - The agreement involves the development of novel small molecule drugs targeting metabolic diseases, with Insilico utilizing its Pharma.AI platform [1] Group 2: Financial Aspects - The total value of the agreement exceeds HKD 931 million, which includes milestone payments for development and sales, as well as a share of subsequent net sales [1]
英矽智能(03696.HK)与齐鲁制药达成超9.31亿港元药物研发合作 加速心血管与代谢类疾病创新疗法开发